New Frontiers for Astrocytic Tumours

Glioblastoma multiforme, the most common type of primary brain tumour, remains an unsolved clinical problem. A great deal of work has been done in an effort to understand the biology and genetics of glioblastoma multiforme, but clinically effective treatments remain elusive. It is well known that ma...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-07, Vol.32 (7), p.2755-2758
Main Authors: NANO, Rosanna, LASCIALFARI, Alessandro, CORTI, Maurizio, PAOLINI, Alessandro, PASI, Francesca, CORBELLA, Franco, DI LIBERTO, Riccardo
Format: Article
Language:English
Subjects:
Astrocytoma - pathology
Astrocytoma - therapy
Biological and medical sciences
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Glioblastoma - pathology
Glioblastoma - therapy
Humans
Hyperthermia, Induced - methods
Magnetics - methods
Medical sciences
Nanoparticles - chemistry
Nanoparticles - therapeutic use
Neurology
Tumors
Tumors of the nervous system. Phacomatoses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma multiforme, the most common type of primary brain tumour, remains an unsolved clinical problem. A great deal of work has been done in an effort to understand the biology and genetics of glioblastoma multiforme, but clinically effective treatments remain elusive. It is well known that malignant gliomas develop resistance to chemo- and radiotherapy. In this review we evaluated the literature data regarding therapeutic progress for the treatment of astrocytic tumours, focusing our attention on new frontiers for glioblastoma. The research studies performed in in vitro and in vivo models show that the application of hyperthermia using magnetic nanoparticles is safe and could be a promising tool in the treatment of glioblastoma patients. Our efforts are focused towards new fields of research, for example nanomedicine and the study of the uptake and cytotoxic effects of magnetic nanoparticles. The improvement of the quality of life of patients, by increasing their survival rate is the best result to be pursued, since these tumours are considered as ineradicable.
ISSN:0250-7005
1791-7530